Get your free personalized podcast brief

We scan new podcasts and send you the top 5 insights daily.

Belantamab mafodotin remains effective following BCMA CAR-T failure because antibody-drug conjugates do not depend on functional T cells for cytotoxicity. Moreover, rising soluble BCMA levels upon disease progression indicate that surface BCMA remains present and re-targetable.

Related Insights

In the Cartitude 1 trial, the strongest predictor of long-term remission with Siltacel was a lower burden of disease (measured by bone marrow percentage and soluble BCMA levels), rather than the number of prior treatments. This implies using CAR-T therapy earlier in the disease course is more effective.

Clinicians must weigh the immediate benefit of using community-accessible belantumab against the risk of reducing the efficacy of future BCMA-targeted therapies like CAR-T or bispecifics. This decision hinges on a patient's ability to travel and access advanced care, creating a complex treatment sequencing challenge.

A convergence of data from pivotal trials (MAJESTIC, CARTITUDE) establishes that BCMA-directed therapies, including CAR-T and bispecifics, provide superior outcomes in early relapse. This marks a paradigm shift, making them the new standard of care after initial therapy failure, even in patients refractory to prior common treatments.

Using a BCMA bispecific antibody first can exhaust a patient's T-cells or cause tumors to lose the BCMA target, rendering a subsequent BCMA-targeted CAR-T therapy ineffective. The optimal sequence is CAR-T first, which preserves T-cell function and BCMA expression, leaving bispecifics as a viable later-line option.

In a heavily pretreated population, mezigdemide plus dexamethasone achieved a 50% response rate in patients refractory to prior BCMA-based approaches, including antibody-drug conjugates, bispecifics, and CAR T-cell therapy. This demonstrates a distinct mechanism that can overcome resistance to the latest immunotherapies.

Belantamab's primary mechanism, immunogenic cell death, does not exhaust T-cells. This unique quality allows clinicians to use it as a first BCMA-targeted agent without compromising the efficacy of subsequent T-cell redirecting therapies like CAR T or bispecifics.

Unlike CAR T and bispecifics, the antibody-drug conjugate Belantamab doesn't rely on T-cell function. This makes it a strategic choice for patients who have previously received T-cell engaging therapies, allowing their T-cells to recover while still providing an effective BCMA-targeted treatment.

Clinicians report significant and durable responses using Belantamab in patients who have relapsed after BCMA-targeted CAR-T. This success may be due to Belantamab's immunogenic mechanism, which doesn't rely on endogenous T-cells and may favorably interact with the post-CAR immune environment.

Before initiating a CD20-targeting bispecific antibody in patients who have failed CAR-T therapy, a new biopsy is mandatory. Up to 30% of these patients experience CD20 antigen loss, which would render the bispecific therapy ineffective and necessitates choosing a drug with a different target.

When choosing between BCMA-directed therapies, using CAR-T therapy first may be strategically advantageous. Early evidence suggests continuous T-cell engager (bispecific) therapy may exert more selective pressure, leading to a higher risk of BCMA target loss through mutation or deletion compared to one-time CAR-T infusions.